High Throughput Screening Market to Hit $45.90 Billion by 2031 as Drug Discovery Spending Rises
Updated
Updated · PR Newswire · May 20
High Throughput Screening Market to Hit $45.90 Billion by 2031 as Drug Discovery Spending Rises
3 articles · Updated · PR Newswire · May 20
$45.90 billion is the projected size of the high-throughput screening market in 2031, up from $27.66 billion in 2026, implying a 10.7% annual growth rate.
Drug discovery demand is driving that expansion as pharmaceutical and biotech companies boost R&D and adopt automated liquid handling, microplate readers, high-content imaging and data-analysis software to screen libraries faster.
Products made up about 85% of the market in 2025, with reagents, kits and consumables alone accounting for roughly 61%, while primary screening services held the largest services share.
CROs and CDMOs are forecast to post the fastest growth through 2031 as more early-stage discovery and screening work is outsourced to cut capital costs and access specialized platforms.
North America held about 43% of the market in 2025, supported by US drug-discovery activity, advanced lab infrastructure and broad uptake of AI-enabled screening tools.
With AI now predicting drug candidates, is traditional high throughput screening becoming obsolete?
As screening gets faster, why do drug development costs and timelines continue to escalate?
How is the new BIOSECURE Act redefining winners and losers in the global drug discovery race?